Jump to navigation

  • IHME
  • GHDx
  • GBD Compare
Home
Main menu
  • Home
  • Results
    • GBD Results Tool
    • Data Visualizations
    • Country Profiles
    • GBD 2019 Cause and Risk Summaries
    • US Health
    • Policy Reports
    • Research Articles
    • Infographics
    • Topics
    • Data & Tools
  • News & Events
    • News
    • Commentaries
    • Events
    • Videos
    • Acting on Data
      • IHME Foundations
  • Projects
    • COVID-19 resources
    • Global Burden of Disease (GBD)
    • Center for Health Trends and Forecasts (CHTF)
    • Disease Control Priorities Network (DCPN)
    • View all
  • Get Involved
    • Donate
    • Careers
    • Call for Collaborators
    • The Roux Prize
    • Murray-Lopez Award
    • Online Training
    • Courses
    • Degree programs
    • Workshops
  • About
    • Racism is a public health issue.
    • Our Principles
    • Faculty
    • Senior Management Team
    • Governance
    • History
    • GHDx
    • Terms and Conditions
    • Contact Us

Explore section

Results

  • GBD Results Tool
  • Data Visualizations
  • Country Profiles
  • GBD 2019 Cause and Risk Summaries
  • US Health
  • Policy Reports
  • Research Articles
  • Infographics
  • Topics
  • Data & Tools

Acute lymphoid leukemia — Level 4 cause


Summary There were 153 000 incident cases (95% UI 129 000–171 000), 47 600 deaths (39 400–53 000), and 2·66 million (2·19–3·01) DALYs due to acute lymphoid leukaemia globally in 2019.

Definition This cause includes death and disability resulting from invasive neoplasms of the blood and bone marrow (specifically acute lymphoid leukaemia), including ICD-10 codes such as C91.0.

Total sources
Incidence 1061
Prevalence 3
Remission 0
Causes of death 2872
Other 0
Table 1: Total sources used in GBD 2019 estimation
What is new in GBD 2019?
  • •New location-years of population-based cancer registry data were added, with a focus on paediatric cancer data.
  • •Mortality-to-incidence ratio models included additional data and were modified to perform more smoothing across time and age.
  • •Survival estimation was updated to use age-specific rather than all-ages survival curves, impacting age-specific prevalence and YLD estimates.
Prevalence
Incidence
Deaths
YLLs
YLDs
DALYs
Cases
(millions)
Rate (per 100 000)
Cases
(millions)
Rate (per 100 000)
Deaths
(millions)
Rate (per 100 000)
YLLs
(millions)
Rate (per 100 000)
YLDs
(millions)
Rate (per 100 000)
DALYs
(millions)
Rate (per 100 000)
2019
Both Sexes
0·975
(0·817
to 1·09)
12·3
(10·3
to 13·7)
0·153
(0·129
to 0·171)
2·0
(1·6
to 2·2)
0·0476
(0·0394
to 0·0530)
0·6
(0·5
to 0·7)
2·57
(2·10
to 2·92)
34·8
(28·5
to 39·6)
0·0939
(0·0642
to 0·128)
1·2
(0·8
to 1·6)
2·66
(2·19
to 3·01)
36·0
(29·5
to 41·0)
Females
0·460
(0·350
to 0·553)
11·5
(8·8
to 13·8)
0·0692
(0·0528
to 0·0824)
1·7
(1·3
to 2·1)
0·0195
(0·0150
to 0·0233)
0·5
(0·4
to 0·6)
1·01
(0·765
to 1·24)
27·8
(21·0
to 34·1)
0·0434
(0·0278
to 0·0609)
1·1
(0·7
to 1·5)
1·05
(0·803
to 1·29)
28·9
(22·0
to 35·3)
Males
0·515
(0·405
to 0·591)
13·2
(10·4
to 15·1)
0·0841
(0·0664
to 0·0962)
2·2
(1·7
to 2·5)
0·0282
(0·0222
to 0·0319)
0·7
(0·6
to 0·8)
1·56
(1·21
to 1·79)
41·7
(32·1
to 48·1)
0·0504
(0·0339
to 0·0699)
1·3
(0·9
to 1·8)
1·61
(1·25
to 1·85)
43·0
(33·3
to 49·5)
Percentage change 2010-19
Both Sexes
52·0%
(33·2
to 68·1)
31·9%
(15·7
to 45·9)
34·9%
(20·6
to 49·1)
17·6%
(4·9
to 29·6)
4·7%
(–4·9
to 15·2)
–7·0%
(–15·6
to 2·4)
–2·6%
(–13·2
to 9·7)
–9·5%
(–19·4
to 2·2)
45·4%
(28·4
to 60·5)
25·7%
(11·0
to 38·9)
–1·5%
(–12·2
to 10·7)
–8·7%
(–18·7
to 2·9)
Females
52·6%
(29·6
to 74·1)
31·9%
(11·7
to 50·0)
36·9%
(17·3
to 54·9)
18·5%
(1·4
to 33·8)
4·6%
(–9·1
to 17·0)
–8·0%
(–20·1
to 3·2)
–3·8%
(–18·8
to 10·4)
–11·2%
(–25·0
to 2·4)
46·6%
(25·0
to 66·5)
26·1%
(7·9
to 43·2)
–2·4%
(–17·5
to 11·8)
–10·2%
(–24·2
to 3·3)
Males
51·4%
(28·5
to 72·7)
31·8%
(12·2
to 50·0)
33·4%
(16·2
to 50·9)
16·8%
(1·7
to 32·1)
4·8%
(–6·7
to 17·8)
–6·4%
(–16·3
to 4·9)
–1·9%
(–14·2
to 12·6)
–8·4%
(–20·1
to 5·1)
44·4%
(23·9
to 64·8)
25·3%
(7·6
to 42·7)
–0·9%
(–13·3
to 13·4)
–7·7%
(–19·3
to 5·7)
Numbers in parentheses are 95% uncertainty intervals.
Table 2: Global prevalence, incidence, deaths, YLLs, YLDs, and DALYs in counts and age-standardised rates for both sexes combined, females, and males in 2019, with percentage change between 2010 and 2019
Deaths YLLs YLDs DALYs
1990 121st 92nd 237th 136th
2010 121st 105th 228th 150th
2019 119th 103rd 225th 150th
Table 3: Rank among most detailed causes for global deaths, YLLs, YLDs, and DALYs in 1990, 2010, and 2019, for both sexes combined
Figure 1: Composition of DALYs by YLLs and YLDs for both sexes combined, 2019
Figure 2: Percentage of DALYs attributable to top risk factors for both sexes combined, 2019
No Legend
Figure 3: Age-standardised DALY rates for each location by SDI, both sexes combined, 2019
Figure 4: Composition of DALYs by YLLs and YLDs, age group, and sex, in 2019
No Legend
Figure 5: Age-standardised DALY rates by (per 100 000) location, both sexes combined, 2019

Results

  • GBD Results Tool
  • Data Visualizations
  • Country Profiles
  • GBD 2019 Cause and Risk Summaries
  • US Health
  • Policy Reports
  • Research Articles
  • Infographics
  • Topics
  • Data & Tools

Stay connected

     

IHME

Institute for Health Metrics and Evaluation

Population Health Building/Hans Rosling Center

3980 15th Ave. NE, Seattle, WA 98195

UW Campus Box #351615

Tel: +1-206-897-2800

Fax: +1-206-897-2899

© 2020 University of Washington

  • Privacy policy
  • Login

  • Home
  • Results
    • GBD Results Tool
    • Data Visualizations
    • Country Profiles
    • GBD 2019 Cause and Risk Summaries
    • US Health
    • Policy Reports
    • Research Articles
    • Infographics
    • Topics
    • Data & Tools
  • News & Events
    • News
    • Commentaries
    • Events
    • Videos
    • Acting on Data
  • Projects
    • COVID-19 resources
    • Global Burden of Disease (GBD)
    • Center for Health Trends and Forecasts (CHTF)
    • Disease Control Priorities Network (DCPN)
    • View all
  • Get Involved
    • Donate
    • Careers
    • Call for Collaborators
    • The Roux Prize
    • Murray-Lopez Award
    • Online Training
    • Courses
    • Degree programs
    • Workshops
  • About
    • Racism is a public health issue.
    • Our Principles
    • Faculty
    • Senior Management Team
    • Governance
    • History
    • GHDx
    • Terms and Conditions
    • Contact Us

Projects

  • Global Burden of Disease (GBD)
  • Disease Control Priorities Network (DCPN)
  • ABCE+: A Focus on Antiretroviral Therapy (ART)
  • Access, Bottlenecks, Costs, and Equity (ABCE)
  • Efficacy to Effectiveness
  • Viral Load Pilot
  • Salud Mesoamérica Initiative
  • Improving Methods to Measure Comparable Mortality by Cause
  • Verbal Autopsy (VA)
  • Disease Expenditure (DEX)
  • Local Burden of Disease
  • State-level disease burden initiative in India
  • US Counties Drivers of Health Study
  • University of Washington Center for Health Trends and Forecasts